Compare MSFT & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSFT | NVO |
|---|---|---|
| Founded | 1975 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1T | 197.4B |
| IPO Year | 2008 | N/A |
| Metric | MSFT | NVO |
|---|---|---|
| Price | $365.07 | $47.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 36 | 11 |
| Target Price | ★ $573.11 | $51.00 |
| AVG Volume (30 Days) | ★ 31.2M | 11.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.86% | ★ 3.19% |
| EPS Growth | ★ 15.59 | N/A |
| EPS | ★ 13.14 | N/A |
| Revenue | ★ $62,484,000,000.00 | N/A |
| Revenue This Year | $18.76 | N/A |
| Revenue Next Year | $15.73 | $3.70 |
| P/E Ratio | $28.50 | ★ $13.60 |
| Revenue Growth | ★ 6.93 | N/A |
| 52 Week Low | $356.28 | $35.12 |
| 52 Week High | $555.45 | $71.80 |
| Indicator | MSFT | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 64.55 |
| Support Level | $356.28 | $45.62 |
| Resistance Level | $426.12 | $47.79 |
| Average True Range (ATR) | 10.41 | 1.39 |
| MACD | -4.78 | 0.40 |
| Stochastic Oscillator | 1.45 | 95.31 |
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.